VIRTUAL LUNCH MEETING

THE POWER OF DEBRIDING WITH DEBRISOFT®

8 JUNE 2021
MAGS MORRISON
JAMES INGLE

LUNCHTIME
13:00 - 13:45
The power of debriding with Debrisoft®

Mags Morrison
Brand Manager/Regional Clinical Advisor
&
James Ingle
Account Manager
L&R Medical UK
Objectives

At the end of this session you will:

• Understand what wound debridement is, who can debride and the purpose of debridement
• Understand in more detail mechanical debridement
• Understand what comprises the Debrisoft® range
• Understand the meaning of ‘Debrisofting’
• Be aware of new clinical evidence.
Today’s meeting

- Theory of debridement: what, who, why?
- Mechanical debridement
- The Debrisoft® Family
- Debrisofting
- New evidence
- Q&A
Debridement is defined as removal of foreign matter, dead or damaged tissue and debris.\textsuperscript{1}
Who can debride?

• Any healthcare professional, e.g. by applying a wound dressing using autolytic debridement

• Some methods of debridement are easy to use and require very little training and are therefore ideal for general use and self-care, e.g. modern mechanical debridement (Monofilament Fibre Technology)

• Certain methods of debridement require extra knowledge, skills and competencies (e.g. surgical and sharp debridement, application of larvae and the more technical solutions).
Because devitalised tissue:
- Is a physical barrier to healing
- May induce chronic inflammation
- Can prevent effectiveness of topical treatments
- May cause underestimation of the wound depth
- Is a source of nutrients for bacteria
- Can mask or mimic signs of infection
- Can contribute to a septic response.

Why debride?
Why debride?

Wounds treated with frequent debridement result in significantly shorter healing time.²
Wounds treated with frequent debridement result in significantly shorter healing time.\textsuperscript{2}
What happens if we do not debride?

- The healing process is impeded
- Exudate volume may increase
- The surrounding skin may become damaged
- Bacteria will proliferate
- The wound may become malodorous
- Wound infection may develop.
What is mechanical debridement?

- The process of physically removing devitalised tissue from the wound bed\(^3\)
- Modern mechanical debridement is typically carried out using single-use products specifically designed to remove barriers to healing\(^3\)
- These solutions offer a quick and effective form of debridement that require no specialist training\(^3\)
- Can be used to physically disrupt wound biofilm\(^3\)
- Can be used for acute and chronic wounds.\(^3\)
The Debrisoft® family

The Debrisoft® Family

Debrisoft® Lolly
Ideal for Cavity wounds e.g. DFU

Debrisoft® Pad (10cm x 10cm)
Ideal for shallow wounds e.g. leg ulcers

Debrisoft® Pad (13cm x 29cm)
Ideal for wounds or hyperkeratosis associated with oedema
How does Debrisoft® work?

• The flexible monofilament fibres, cut to an angled tip are designed to reach all areas of the uneven wound bed

• The fibre tips actively loosen debris and devitalised tissue from the wound

• Debris and keratoses are efficiently removed, even from the surrounding skin

• The fibre composite absorbs and binds the loosened debris and keratoses.
Debrisoft®, the most evidenced form of mechanical debridement:

- Over 100 pieces of clinical evidence on 2929 patients
- Debrisoft® is the only form of mechanical debridement recommended by the National Institute for Health and Care Excellence (NICE).⁴

The NICE committee concluded that the technology is:

- Well tolerated by patients
- Likely to debride wounds more quickly
- Which can result in fewer nurse visits
- More cost-effective than other debridement methods.
The power of Debrisothing

New evidence:

- The aim of the audit was to investigate the impact of Debrisothing on wound treatment costs
The power of Debrisofting

By integrating appropriate use of Debrisoft® into wound care practice, significant potential savings on prescribing spend could be realised.
The value of Debrisofting

TOTAL 6 MONTHS PRESCRIBED WOUND CARE EXPENDITURE ON SELECTED 486 PATIENTS

£101,723

£712,467

£610,744
Reduction in patients receiving wound care prescriptions
# Prescribing savings

<table>
<thead>
<tr>
<th>Dressing</th>
<th>6-months before Debrisoft (£)</th>
<th>6-months after Debrisoft (£)</th>
<th>Difference (£)</th>
<th>Percentage fall (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial dressing</td>
<td>146,611.51</td>
<td>97,566.28</td>
<td>49,045.23</td>
<td>33.45</td>
</tr>
<tr>
<td>Antimicrobial other</td>
<td>4565.41</td>
<td>4141.42</td>
<td>423.99</td>
<td>9.29</td>
</tr>
<tr>
<td>Negative pressure dressing</td>
<td>14,134.97</td>
<td>10,116.82</td>
<td>4018.15</td>
<td>28.43</td>
</tr>
<tr>
<td>Negative pressure other</td>
<td>4370.16</td>
<td>1591.14</td>
<td>2779.02</td>
<td>63.59</td>
</tr>
<tr>
<td>Non-medicated dressing</td>
<td>532,910.53</td>
<td>447,457.49</td>
<td>85,453.04</td>
<td>16.04</td>
</tr>
<tr>
<td>Non-medicated other</td>
<td>9874.05</td>
<td>7399.37</td>
<td>2474.68</td>
<td>25.06</td>
</tr>
<tr>
<td>Total</td>
<td>712,466.63</td>
<td>568,272.52</td>
<td>144,194.11</td>
<td>20.24</td>
</tr>
<tr>
<td>Debrisoft</td>
<td>0.00</td>
<td>42,471.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Totals inc. Debrisoft</td>
<td>712,466.63</td>
<td>610,744.28</td>
<td>101,722.35</td>
<td>14.28</td>
</tr>
<tr>
<td>Dressing</td>
<td>6-months before Debrisoft (£)</td>
<td>6-months after Debrisoft (£)</td>
<td>Difference (£)</td>
<td>Percentage fall (£)</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Antimicrobial dressing</td>
<td>146,611.51</td>
<td>97,566.28</td>
<td>49,045.23</td>
<td>33.45</td>
</tr>
<tr>
<td>Antimicrobial other</td>
<td>4565.41</td>
<td>4141.42</td>
<td>423.99</td>
<td>9.29</td>
</tr>
<tr>
<td>Negative pressure dressing</td>
<td>14,134.97</td>
<td>10,116.82</td>
<td>4018.15</td>
<td>28.43</td>
</tr>
<tr>
<td>Negative pressure other</td>
<td>4370.16</td>
<td>1591.14</td>
<td>2779.02</td>
<td>63.59</td>
</tr>
<tr>
<td>Non-medicated dressing</td>
<td>532,910.53</td>
<td>447,457.49</td>
<td>85,453.04</td>
<td>16.04</td>
</tr>
<tr>
<td>Non-medicated other</td>
<td>9874.05</td>
<td>7399.37</td>
<td>2474.68</td>
<td>25.06</td>
</tr>
<tr>
<td>Total</td>
<td>712,466.63</td>
<td>568,272.52</td>
<td>144,194.11</td>
<td>20.24</td>
</tr>
<tr>
<td>Debrisoft</td>
<td>0.00</td>
<td>42,471.76</td>
<td>144,194.11</td>
<td>20.24</td>
</tr>
<tr>
<td>Totals inc. Debrisoft</td>
<td>712,466.63</td>
<td>610,744.28</td>
<td>101,722.35</td>
<td>14.28</td>
</tr>
</tbody>
</table>
## Prescribing savings

<table>
<thead>
<tr>
<th>Dressing</th>
<th>6-months before Debrisoft (£)</th>
<th>6-months after Debrisoft (£)</th>
<th>Difference (£)</th>
<th>Percentage fall (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial dressing</td>
<td>146,611.51</td>
<td>97,566.28</td>
<td>49,045.23</td>
<td>33.45</td>
</tr>
<tr>
<td>Antimicrobial other</td>
<td>4565.41</td>
<td>4141.42</td>
<td>423.99</td>
<td>9.29</td>
</tr>
<tr>
<td>Negative pressure dressing</td>
<td>14,134.97</td>
<td>10,116.82</td>
<td>4018.15</td>
<td>28.43</td>
</tr>
<tr>
<td>Negative pressure other</td>
<td>4370.16</td>
<td>1591.14</td>
<td>2779.02</td>
<td>63.59</td>
</tr>
<tr>
<td>Non-medicated dressing</td>
<td>532,910.53</td>
<td>447,457.49</td>
<td>85,453.04</td>
<td>16.04</td>
</tr>
<tr>
<td>Non-medicated other</td>
<td>9874.05</td>
<td>7399.37</td>
<td>2474.68</td>
<td>25.06</td>
</tr>
<tr>
<td>Total</td>
<td>712,466.63</td>
<td>568,272.52</td>
<td>144,194.11</td>
<td>20.24</td>
</tr>
<tr>
<td>Debrisoft</td>
<td>0.00</td>
<td>42,471.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Totals inc. Debrisoft</td>
<td>712,466.63</td>
<td>610,744.28</td>
<td>101,722.35</td>
<td>14.28</td>
</tr>
</tbody>
</table>
## Prescribing savings

<table>
<thead>
<tr>
<th>Dressing</th>
<th>6-months before Debrisoft (£)</th>
<th>6-months after Debrisoft (£)</th>
<th>Difference (£)</th>
<th>Percentage fall (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial dressing</td>
<td>146,611.51</td>
<td>97,566.28</td>
<td>49,045.23</td>
<td>33.45</td>
</tr>
<tr>
<td>Antimicrobial other</td>
<td>4565.41</td>
<td>4141.42</td>
<td>423.99</td>
<td>9.29</td>
</tr>
<tr>
<td>Negative pressure dressing</td>
<td>14,134.97</td>
<td>10,116.82</td>
<td>4018.15</td>
<td>28.43</td>
</tr>
<tr>
<td>Negative pressure other</td>
<td>4370.16</td>
<td>1591.14</td>
<td>2779.02</td>
<td>63.59</td>
</tr>
<tr>
<td>Non-medicated dressing</td>
<td>532,910.53</td>
<td>447,457.49</td>
<td>85,453.04</td>
<td>16.04</td>
</tr>
<tr>
<td>Non-medicated other</td>
<td>9874.05</td>
<td>7399.37</td>
<td>2474.68</td>
<td>25.06</td>
</tr>
<tr>
<td>Total</td>
<td>712,466.63</td>
<td>568,272.52</td>
<td>144,194.11</td>
<td>20.24</td>
</tr>
<tr>
<td>Debrisoft</td>
<td>0.00</td>
<td>42,471.76</td>
<td>42,471.76</td>
<td>100%</td>
</tr>
<tr>
<td>Totals inc. Debrisoft</td>
<td>712,466.63</td>
<td>610,744.28</td>
<td>101,722.35</td>
<td>14.28</td>
</tr>
</tbody>
</table>
Summary

• Using Debrisoft® is likely to result in a reduction in nurse visits and is potentially less expensive than other debridement methods[^4]

• Debrisoft® could be more cost-effective over the longer term[^3,4]

• Potential savings and reductions on wound care prescriptions for your trust.[^3]


Contact us now

If you would like further information on Debrisoft® or the recent publication:

Email: customer.solutions@uk.lrmed.com

Contact: Your local account manager

Visit: www.Lohmann-Rauscher.co.uk
Download your certificate
www.jcn-live.co.uk/virtual-lunch-meeting